Type 2 Diabetes Clinical Trial
Official title:
Impact of Hypoglycemia on Cardiac Function in Elderly Patients With Diabetes
The risk of hypoglycemia (low blood sugar) associated with the treatment of diabetes increases with age. Hypoglycemia is a common reason for admission to hospital for older patients with diabetes. Older patients are often unaware that their blood sugar is low and asymptomatic hypoglycemia, as assessed by continuous blood sugar monitoring, is frequent in the elderly. There is also evidence that older people with diabetes are more likely to develop cardiovascular events such a heart attack and more likely to die suddenly when compared to older people without diabetes. It is possible that low blood sugar levels contribute to the increased frequency of these events, but this possibility has never been studied. The purpose of this study is to assess how frequently low blood sugar occurs in older patients with diabetes and to see if low blood sugars adversely affect heart function in these patients.
Investigators propose a pilot study in 20 patients over age 70 who have type 2 diabetes and
are being treated with insulin. These patients will be enrolled from the elderly diabetes
clinic at Vancouver General Hospital. Patients will be asked to come to the Gerontology
research laboratory in the Research Pavilion at Vancouver General Hospital. A trained
research nurse will instrument each patient with an iPro2 glucose sensor (Medtronic Canada).
These sensors reliably and continuously measure blood glucose for periods of up to 7 days.
Briefly, the skin will be swabbed with a disinfectant and a small catheter will be inserted
subcutaneously. This needle will be attached to a glucose sensor. Patients will wear this
sensor for 6 days. Patients will measure their glucose using a glucometer 4 times each day
during this period and will also be given a log book to keep track of glucose values.
Patients will also be asked to record any symptoms of hypoglycemia. At the end of 6 days the
sensor will be removed.
At the same time the glucose sensor is started, a trained research nurse will connect the
patient to a single use CardioSTAT ECG recorder. The archived ECG waveforms will be
downloaded for QT and T-wave alternans analysis. The heart rate and QT interval will be
measured at baseline and the end of each interval from the digitized ECG.
Patients and relevant family will be provided with in person education regarding the function
and use of the monitor, implications for bathing and sleep, and contact information for
troubleshooting. Patients will be asked to change the leads at home twice during the 6 days
of the study. Patients will be asked to keep a log book of any cardiac symptoms during the 6
days of the study, as well as their activities. The glucose and CardioSTAT monitor will
undergo time synchronization to ensure ability to do correlative analysis.
This is a feasibility pilot to establish preliminary data for analysis. The CardioSTAT
monitor will allow assessment of cardiac arrhythmias, myocardial ischemia and cardiovascular
autonomic function. The results from the glucose sensor and the CardioSTAT monitor will be
correlated and compared to each other to determine if hypoglycemia has an adverse effect on
heart function. Hypoglycemia is likely to induce autonomic responses captured on the
CardioSTAT monitor and concordant ischemic S-T segment changes if coronary disease is
present. It may also detect any resultant arrhythmias, although ischemic arrhythmias are
uncommon in 6 days of monitoring. If investigators determine that hypoglycemia has negative
effects on cardiac function, investigators may able to design treatments that would prevent
these effects from happening in the future.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |